Global Liver Cancer Diagnostics Market Size 2024, Forecast To 2033
6 Mar, 2024
The liver cancer diagnostics market size has also seen robust growth, increasing from $9.19 billion in 2023 to $9.95 billion in 2024, marking a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to biopsy techniques and histopathology, development of biomarker detection, evolution of screening programs, advances in genetic testing, and improvements in liver imaging modalities. Looking ahead, the market is anticipated to witness strong growth, reaching $12.96 billion in 2028 with a CAGR of 6.8%. The forecast period's growth can be attributed to regulatory changes and standardization, growing importance of imaging modalities, development of next-generation sequencing, expanded screening programs and awareness, and rising demand for biomarker-based testing. Major trends in the forecast period include a rise in incidence and prevalence, advancements in imaging technologies, focus on non-invasive diagnostics, precision medicine and personalized diagnostics, and integration of artificial intelligence (AI).
Global Liver Cancer Diagnostics Market Key Driver
The rising prevalence of liver cancer is expected to propel the growth of the liver cancer diagnostics market going forward. Liver cancer refers to the condition in which the liver cells grow and multiply out of control, giving rise to a life-threatening illness. Liver cancer diagnostic tests are performed to determine whether cancer cells are spreading within the liver or surrounding it after the diagnosis of primary carcinoma of the liver, so the rising prevalence of liver cancer boosts the liver cancer diagnostics market. For instance, in January 2023, according to the Cancer Facts & Figures 2023 report published by the American Cancer Society, a US-based voluntary health organization, the number of new cases of liver and intrahepatic bile duct cancer in females reached 13,230 in 2023, an increase from 12,640 in 2020, in the United States. Furthermore, in 2023, an estimated 41,210 new cases of liver cancer will be diagnosed in the US, where 29,380 people are expected to die. Therefore, the rising prevalence of liver cancer is driving the growth of the liver cancer diagnostic market.
Get A Free Sample Of The Global Liver Cancer Diagnostics Market ReportGlobal Liver Cancer Diagnostics Market Segments
The liver cancer diagnostics market covered in this report is segmented –
1) By Type: Hepatocellular Carcinoma, Cholangiocarcinoma, Hepatoblastoma, Other Types
2) By Screening: Laboratory Testing, Imaging, Endoscopy, Biopsy, Other Screenings
3) By Technology: Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Immunohistochemical (IHC), Other Technologies
4) By End Use: Hospitals And Diagnostic Laboratories, Academic And Research Institutes, Pharmaceutical And CRO Laboratories
By Geography:The regions covered in the liver cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
North America was the largest region in the liver cancer diagnostics market in 2023. The regions covered in the liver cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Liver Cancer Diagnostics Industry Players
Abbott Laboratories, F. Hoffmann-La Roche Ltd., Qiagen NV, Thermo Fisher Scientific Inc., Siemens Healthineers, Becton Dickinson & Company, Illumina Inc., Koninklijke Philips NV, Epigenomics AG, Charles Russell Bard, Hologic Inc., Digna Biotech SL, Biocept Inc., Danaher Corporation, Foundation Medicine Inc., Agilent Technologies Inc., Biocare Medical LLC, Genemed Biotechnologies Inc., Merck KGaA, Fujifilm Medical Systems USA Inc., GE Healthcare, Bio SB Inc., Advanced Cell Diagnostics Inc., Oxford Gene Technology, Leica Biosystems Nussloch GmbH, Exiqon A/S, BioGenex Laboratories Inc., OncoCyte Corporation, Guardant Health Inc., Exact Sciences Corporation, Grail Inc., Freenome Holdings Inc., Natera Inc., Personal Genome Diagnostics Inc., Thrive Earlier Detection Corp
Get The Full Global Liver Cancer Diagnostics Market Report
Liver Cancer Diagnostics Market Overview
Liver cancer diagnostics refers to the various methods employed to detect and diagnose liver cancer, a type of cancer that originates in the liver. It is used for the early detection and diagnosis of liver cancer via imaging and molecular testing.
Liver Cancer Diagnostics Global Market Report 2023 provides data on the global liver cancer diagnostics market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The liver cancer diagnostics market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.